Literature DB >> 12242449

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes.

Mark E Dudley1, John R Wunderlich, Paul F Robbins, James C Yang, Patrick Hwu, Douglas J Schwartzentruber, Suzanne L Topalian, Richard Sherry, Nicholas P Restifo, Amy M Hubicki, Michael R Robinson, Mark Raffeld, Paul Duray, Claudia A Seipp, Linda Rogers-Freezer, Kathleen E Morton, Sharon A Mavroukakis, Donald E White, Steven A Rosenberg.   

Abstract

We report here the adoptive transfer, to patients with metastatic melanoma, of highly selected tumor-reactive T cells directed against overexpressed self-derived differentiation antigens after a nonmyeloablative conditioning regimen. This approach resulted in the persistent clonal repopulation of T cells in those cancer patients, with the transferred cells proliferating in vivo, displaying functional activity, and trafficking to tumor sites. This led to regression of the patients' metastatic melanoma as well as to the onset of autoimmune melanocyte destruction. This approach presents new possibilities for the treatment of patients with cancer as well as patients with human immunodeficiency virus-related acquired immunodeficiency syndrome and other infectious diseases.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12242449      PMCID: PMC1764179          DOI: 10.1126/science.1076514

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  25 in total

Review 1.  Maintaining the norm: T-cell homeostasis.

Authors:  Stephen C Jameson
Journal:  Nat Rev Immunol       Date:  2002-08       Impact factor: 53.106

2.  Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma.

Authors:  S A Rosenberg; J C Yang; D J Schwartzentruber; P Hwu; F M Marincola; S L Topalian; N P Restifo; M E Dudley; S L Schwarz; P J Spiess; J R Wunderlich; M R Parkhurst; Y Kawakami; C A Seipp; J H Einhorn; D E White
Journal:  Nat Med       Date:  1998-03       Impact factor: 53.440

3.  A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma.

Authors:  Mark E Dudley; John R Wunderlich; James C Yang; Patrick Hwu; Douglas J Schwartzentruber; Suzanne L Topalian; Richard M Sherry; Francesco M Marincola; Susan F Leitman; Claudia A Seipp; Linda Rogers-Freezer; Kathleen E Morton; Azam Nahvi; Sharon A Mavroukakis; Donald E White; Steven A Rosenberg
Journal:  J Immunother       Date:  2002 May-Jun       Impact factor: 4.456

4.  Syngeneic adoptive immunotherapy and chemoimmunotherapy of a Friend leukemia: requirement for T cells.

Authors:  J R Berenson; A B Einstein; A Fefer
Journal:  J Immunol       Date:  1975-07       Impact factor: 5.422

5.  Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma.

Authors:  M E Dudley; J Wunderlich; M I Nishimura; D Yu; J C Yang; S L Topalian; D J Schwartzentruber; P Hwu; F M Marincola; R Sherry; S F Leitman; S A Rosenberg
Journal:  J Immunother       Date:  2001 Jul-Aug       Impact factor: 4.456

6.  Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation.

Authors:  R Childs; A Chernoff; N Contentin; E Bahceci; D Schrump; S Leitman; E J Read; J Tisdale; C Dunbar; W M Linehan; N S Young; A J Barrett
Journal:  N Engl J Med       Date:  2000-09-14       Impact factor: 91.245

7.  Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects.

Authors:  R T Mitsuyasu; P A Anton; S G Deeks; D T Scadden; E Connick; M T Downs; A Bakker; M R Roberts; C H June; S Jalali; A A Lin; R Pennathur-Das; K M Hege
Journal:  Blood       Date:  2000-08-01       Impact factor: 22.113

8.  Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response.

Authors:  S A Rosenberg; J C Yang; D E White; S M Steinberg
Journal:  Ann Surg       Date:  1998-09       Impact factor: 12.969

9.  Epitope-specific evolution of human CD8(+) T cell responses from primary to persistent phases of Epstein-Barr virus infection.

Authors:  Andrew D Hislop; Nicola E Annels; Nancy H Gudgeon; Alison M Leese; Alan B Rickinson
Journal:  J Exp Med       Date:  2002-04-01       Impact factor: 14.307

10.  Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo.

Authors:  C Yee; J A Thompson; P Roche; D R Byrd; P P Lee; M Piepkorn; K Kenyon; M M Davis; S R Riddell; P D Greenberg
Journal:  J Exp Med       Date:  2000-12-04       Impact factor: 14.307

View more
  925 in total

1.  T cells take aim at cancer.

Authors:  Drew Pardoll
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-02       Impact factor: 11.205

Review 2.  Adoptive therapy with CD8(+) T cells: it may get by with a little help from its friends.

Authors:  William Y Ho; Cassian Yee; Philip D Greenberg
Journal:  J Clin Invest       Date:  2002-11       Impact factor: 14.808

Review 3.  Adoptive transfer of unselected or leukemia-reactive T-cells in the treatment of relapse following allogeneic hematopoietic cell transplantation.

Authors:  Richard J O'Reilly; Tao Dao; Guenther Koehne; David Scheinberg; Ekaterina Doubrovina
Journal:  Semin Immunol       Date:  2010-05-26       Impact factor: 11.130

4.  Naive CD4+ T Cells Carrying a TLR2 Agonist Overcome TGF-β-Mediated Tumor Immune Evasion.

Authors:  Mohsen Ibrahim; Davide Scozzi; Kelsey A Toth; Donatella Ponti; Daniel Kreisel; Cecilia Menna; Elena De Falco; Antonio D'Andrilli; Erino A Rendina; Antonella Calogero; Alexander S Krupnick; Andrew E Gelman
Journal:  J Immunol       Date:  2017-12-06       Impact factor: 5.422

Review 5.  Re-adapting T cells for cancer therapy: from mouse models to clinical trials.

Authors:  Ingunn M Stromnes; Thomas M Schmitt; Aude G Chapuis; Sunil R Hingorani; Philip D Greenberg
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

Review 6.  Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells.

Authors:  Michael C Jensen; Stanley R Riddell
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

Review 7.  Drug development in the era of precision medicine.

Authors:  Sarah A Dugger; Adam Platt; David B Goldstein
Journal:  Nat Rev Drug Discov       Date:  2017-12-08       Impact factor: 84.694

Review 8.  Immunotherapy in gastric cancer.

Authors:  Satoko Matsueda; David Y Graham
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

Review 9.  Chemoimmunotherapy: reengineering tumor immunity.

Authors:  Gang Chen; Leisha A Emens
Journal:  Cancer Immunol Immunother       Date:  2013-02-07       Impact factor: 6.968

Review 10.  Immunomodulation in the treatment of haematological malignancies.

Authors:  Michela Cesco-Gaspere; Emma Morris; Hans J Stauss
Journal:  Clin Exp Med       Date:  2009-02-24       Impact factor: 3.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.